Evidence map›Paper›PMID 39464114›Full record

ArticlebioRxiv : the preprint server for biology2024

Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy.

Jacob Bridge, Matthew J Johnson, Jihyun Kim, Sophia Wenthe, Joshua Krueger, Bryce Wick, Mitchell Kluesner, Andrew T Crane, Jason Bell, Joseph G Skeate and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Jacob BridgeDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Matthew J JohnsonDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Jihyun KimDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Sophia WentheDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Joshua KruegerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Bryce WickDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Mitchell KluesnerMolecular and Cellular Biology Graduate Program, University of Washington, Seattle, WA, USA.
Andrew T CraneDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Jason BellDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Joseph G SkeateDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Branden S MoriarityDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Beau R WebberDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-VirotherapyU54CA232561 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI CAIRO, MITCHELL S., CRIPE, TIMOTHY P · 2019 to 2023
$12.1M
Project 3P01CA254849 · NCI · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW, MASOPUST, DAVID · 2021 to 2025
$9.4M
TECH CoreU54CA268069 · NCI · UNIVERSITY OF MINNESOTA · PI David J. Odde · 2022 to 2026
$8.2M
SCGE Disease Models Studies Supplement: Evaluation of prime editing for the amelioration of alpha-1-antitrypsin deficiency in murine and porcine models.U24OD026641 · OD · RECOMBINETICS, INC. · PI CARLSON, DANIEL FRED · 2018 to 2022
$4.1M
Activated NK CAR Cells to Cure HIVR01AI161017 · NIAID · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S, SKINNER, PAMELA J · 2021 to 2025
$3.8M
Engineered B Cells as a Universal Platform for the Treatment of EnzymopathiesR01AI146009 · NIAID · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S · 2020 to 2024
$1.9M
Multiplex Engineered Human Lymphocytes for Therapeutic Protein DeliveryR21AI163731 · NIAID · UNIVERSITY OF MINNESOTA · PI WEBBER, BEAU RICHARD · 2021 to 2022
$426k
Determining the cell of origin in Ewing sarcoma through genomic analysisR21CA237789 · NCI · UNIVERSITY OF MINNESOTA · PI SPECTOR, LOGAN G., WEBBER, BEAU RICHARD · 2020 to 2021
$396k
NCI NIH HHS P01 CA254849NCI NIH HHS P30 CA077598NCI NIH HHS P50 CA136393NCI NIH HHS R21 CA237789NCI NIH HHS U54 CA232561NCI NIH HHS U54 CA268069NIAID NIH HHS R01 AI146009NIAID NIH HHS R01 AI161017NIAID NIH HHS R21 AI163731NIH HHS U24 OD026641
6 · The paper itself

Abstract

Gamma delta (γδ) T cells are defined by their unique ability to recognize a limited repertoire of non-peptide, non-MHC-associated antigens on transformed and pathogen-infected cells. In addition to their lack of alloreactivity, γδ T cells exhibit properties distinct from other lymphocyte subsets, prompting significant interest in their development as an off-the-shelf cellular immunotherapeutic. However, their low abundance in circulation, heterogeneity, limited methods for

Identifiers

PMID39464114
PMCPMC11507710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.